Pfizer 24 December 2025 - 28 June 2026

Pfizer Inc. is starting the week stuck after shares fell Friday. Investors have yet to see if a better quarter is enough for ongoing growth. With U.S. markets shut over the weekend, PFE last traded at $25.33 on Friday.

Pfizer ended Thursday down 1.6% at $26.86, caught up in a sweeping selloff across U.S. equities. Oil prices jumped on intensifying Middle East tensions, and the slide hit all three major indexes—S&P 500, Dow, and Nasdaq—each losing over 1.5%.

Pfizer slipped 0.3% to $27.52 ahead of the bell Wednesday, following a 2.1% gain Tuesday that took shares to $27.61. The stock hit $27.73 during the session, with trading volume reaching roughly 43.6 million shares.

Pfizer shares climbed 0.8% to $27.01 by 12:43 p.m. EST, building on a rebound after a volatile stretch triggered by fresh trial data and a quarterly earnings report.

Pfizer Inc shares last traded at $24.90, down 0.4% from the previous close, with U.S. markets closed on Thursday for the New Year’s Day holiday. Reuters reported Pfizer is leading a new round of U.S. list-price increases for 2026, planning hikes on around 80 drugs and vaccines — including a 15% rise for its COVID-19 shot Comirnaty — as drugmakers overall line up price increases on at least 350 branded medicines, with a median hike of about 4%. “They really just nibble around the margins,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital, while Pfizer said its average increase for innovative medicines and vaccines would be below inflation. Reuters

Pfizer Inc shares were last indicated slightly lower after hours on Wednesday after a report said the drugmaker plans to raise U.S. list prices on about 80 medicines in 2026. U.S. stock markets were closed on Thursday for the New Year’s Day holiday.

Pfizer Inc. shares fell about 0.4% to $24.90 in after-hours trading on Wednesday, after a report said the drugmaker is leading a wave of U.S. list-price increases set for 2026. The data, compiled by healthcare research firm 3 Axis Advisors, showed drugmakers plan hikes on at least 350 branded medicines, with Pfizer accounting for around 80 increases, including a 15% rise for its COVID vaccine Comirnaty. “They really just nibble around the margins,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital in Boston. Reuters

Pfizer shares were down 0.1% at $24.96 in afternoon trade on Wednesday after a Reuters report said the drugmaker plans U.S. list-price hikes on about 80 medicines in 2026. Reuters

Pfizer Inc. stock is spending Christmas Eve in the familiar “mid-$20s” zone — a level that has become a psychological battleground for investors trying to decide whether Pfizer is a high-yield value play, a turnaround story, or simply a “show-me” stock until growth returns.